Literature DB >> 816689

An assessment of investigations conducted in the USA on Brucella abortus strain 45/20 bacterins.

W C Ray.   

Abstract

The results of five investigations in cattle using 45/20 Bacterins are presented and evaluated. Seemingly contradictory results may be the result of one or more modifications in project design or in procedures. In these trials, there appeared to be no significant difference in the level of protection for cattle when using either intramuscular or subcutaneous routes of injection or when 10 or 12 week intervals between doses were used in cattle 6 months of age or older. Also, the relative resistance to subsequent exposure was not significantly different in which only 45/20 Bacterins were administered. There were apparent differences in protection between cattle receiving one versus two doses of 45/20 Bacterin or initially vaccinated with 45/20 Bacterin at 3 months of age and again 15 weeks later compared to older age groups vaccinated at 10 or 12 week intervals between doses. The disproportionate infection rate among 45/20 vaccinated animals in the last completed investigation suggests that cattle in infected herds subjected to multiple exposures to virulent organisms do not develop adequate resistance. Local and systemic reactions following the administration of 45/20 Bacterin were also noted in some groups.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 816689

Source DB:  PubMed          Journal:  Dev Biol Stand        ISSN: 0301-5149


  2 in total

1.  Immunity to Brucella in mice vaccinated with a fraction (F8) or a killed vaccine (H38) with or without adjuvant. Level and duration of immunity in relation to dose of vaccine, recall injection and age of mice.

Authors:  N Bosseray
Journal:  Br J Exp Pathol       Date:  1978-08

2.  Vaccination with Brucella abortus rough mutant RB51 protects BALB/c mice against virulent strains of Brucella abortus, Brucella melitensis, and Brucella ovis.

Authors:  M P Jiménez de Bagüés; P H Elzer; S M Jones; J M Blasco; F M Enright; G G Schurig; A J Winter
Journal:  Infect Immun       Date:  1994-11       Impact factor: 3.441

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.